Donepezil treatment of severe Alzheimer's disease: Results from a 24-week, multinational, placebo-controlled trial.

被引：0
|
作者：
Black, S
Li, H
McRae, T
Richardson, S
机构：
[1] Sunnybrook & Womens Coll, Toronto, ON, Canada
[2] Eisai Inc, Teaneck, NJ USA
[3] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2006年 / 54卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S71 / S71
页数：1
相关论文
共 50 条
  • [1] Donepezil treatment of severe Alzheimer's disease: Results from a 24-week, multinational, randomized, double-blind, placebo-controlled trial
    Black, S.
    Li, H.
    McRae, T.
    Richardson, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 69 - 69
  • [2] Treatment of severe Alzheimer's disease with donepezil: Results from a 24-week, multinational, randomized, double-blind, placebo-controlled trial
    Black, S
    Li, HL
    McRae, T
    Richardson, S
    NEUROLOGY, 2006, 66 (05) : A347 - A347
  • [3] Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, Randomized trial
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Ohbayashi, Toshio
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (05) : 399 - 407
  • [4] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
    Rogers, SL
    Farlow, MR
    Doody, RS
    Mohs, R
    Friedhoff, LT
    Albala, B
    Baumel, B
    Booker, G
    Dexter, J
    Farmer, M
    Feighner, JP
    Ferris, S
    Gordon, B
    Gorman, DG
    Hanna, G
    Harrell, LE
    Hubbard, R
    Kennedy, J
    McCarthy, J
    Scharre, DW
    Schaerf, F
    Schneider, L
    Seltzer, B
    Siegal, A
    Stark, SR
    Strauss, A
    Walshe, TM
    NEUROLOGY, 1998, 50 (01) : 136 - 145
  • [5] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - Pilot Study
    Prasher, VP
    Huxley, A
    Haque, MS
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (03) : 270 - 278
  • [6] Effects of Rivastigmine on Executive Function in Parkinson's Disease Dementia: Results from a 24-Week Placebo-Controlled Clinical Trial
    Schmitt, Frederick
    Farlow, Martin
    Olin, Jason
    ANNALS OF NEUROLOGY, 2009, 66 : S48 - S48
  • [7] Efficacy and tolerability of donepezil in vascular dementia -: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial
    Black, S
    Román, GC
    Geldmacher, DS
    Salloway, S
    Hecker, J
    Burns, A
    Perdomo, C
    Kumar, D
    Pratt, R
    STROKE, 2003, 34 (10) : 2323 - 2330
  • [8] The effects of donepezil in Alzheimer's disease -: Results from a multinational trial
    Burns, A
    Rossor, M
    Hecker, J
    Gauthier, S
    Petit, H
    Möller, HJ
    Rogers, SL
    Friedhoff, LT
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) : 237 - 244
  • [9] A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    NEUROLOGY, 2001, 57 (04) : 613 - 620
  • [10] Donepezil improves cognition in patients with vascular dementia: Results from study 307, a 24-week, randomized, double-blind, placebo-controlled trial
    Roman, GC
    Pratt, RD
    Perdomo, CA
    Perdomo, CA
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S55 - S55
12345